Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Sep 16;11(9):e0162597. doi: 10.1371/journal.pone.0162597

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Erlendsson et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 2 — The figure depicts the evolution of individual local skin responses (LSR) in mice treated with ingenol mebutate alone (IngMeb; A) and concurrent clobetasol (IngMeb+CP: B). Erythema, bleeding, and vesiculation developed rapidly after IngMeb application peaking on day 1. Flaking and crusting emerged on day 2, culminating on day 3 while ulceration had a delayed onset and reached peak intensity on day 5. Concurrent CP application did not alleviate the LSR but exacerbated all individual responses, including erythema, bleeding, vesiculation, flaking, crusting and ulceration. The skin was normalized by day 10 post-treatment in both IngMeb and IngMeb+CP treated mice.